Pimivalimab

匹米利单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePimivalimab
Drug Alias NameJTX-4014
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJounce Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelgene CorpJounce Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A